Virtual Library
Start Your Search
A. Hasan
Author of
-
+
P2.03a - Poster Session with Presenters Present (ID 464)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03a-021 - Vinorelbine/Carboplatin vs Gemcitabine/Carboplatin in Advanced Squamous Cell Lung Cancer (ID 3996)
14:30 - 14:30 | Author(s): A. Hasan
- Abstract
Background:
Scc accounts for about 30-40% of lung cancer cases, and the majority presents with locally advanced or metastatic disease. Vinorelbine/carboplatin (VC) and gemcitabine/carboplatin (GC) are both third-generation combinations used in the treatment of NSCLC. VC and GC were similar with respect to efficacy, healthrelated quality of life (HRQOL) and toxicity in stage IIIB/IV NSCLC patients.The aim is to compare VC and GC with respect to efficacy , DFS, hematologic toxicity in stage IIIB/IV Scc lung cancer patients.
Methods:
Chemonaive patients with SCC lung cancer stage IIIB/IV and WHO performance status 0–2 were eligible. No upper age limit was defined. Patients received vinorelbine 25 mg m[2] or gemcitabine 1000 mg m[2 ]on days 1 and 8 and carboplatin AUC 4 on day 1 and six courses with 3-week cycles. During 13 months, 103 patients were included (VC, n=53; GC, n=50).
Results:
median DFS was 22 vs 24.5 weeks (p=0.42 ), ORR (3cycle) 49.05% vs 58% and ORR(6cycle) % 16.89 vs %16 in the VC and GC arm, respectively (P=0.48). nausea/vomiting showed no significant differences. More grade 3–4 anemia (P=0.009), thrombocytopenia (P = 0.004) in GC arm . There was more grade 3–4 leucopoenia (P=0.28) in the VC arm, but the rate of neutropenic infections was the same (P=0.87).
Conclusion:
VC and GC are similar in treating advanced SCC lung cancer when regarding ORR and DFS, while grade 3–4 toxicity requiring interventions were less frequent when VC is compared to GC in advanced squamous cell lung cancer.
